Kalpit Patel
Stock Analyst at B. Riley Securities
(0.76)
# 3,854
Out of 4,944 analysts
59
Total ratings
27.91%
Success rate
-13.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DERM Journey Medical | Maintains: Buy | $9 → $12 | $7.25 | +65.52% | 6 | Jul 30, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $40.74 | +47.28% | 5 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $7.35 | +90.48% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $18.05 | +105.04% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $36.58 | -34.39% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.43 | +144.76% | 4 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $8.02 | +12.22% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $5.17 | +93.42% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.16 | +503.45% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $9.59 | +317.10% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $0.86 | +249.65% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $18.86 | +6.07% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $2.93 | +923.89% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $13.45 | +167.66% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.29 | +3,830.13% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.04 | +1,630.77% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.91 | +161.78% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $17.50 | +471.43% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $10.66 | +603.56% | 2 | Sep 3, 2021 |
Journey Medical
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $7.25
Upside: +65.52%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $40.74
Upside: +47.28%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $7.35
Upside: +90.48%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $18.05
Upside: +105.04%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $36.58
Upside: -34.39%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.43
Upside: +144.76%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $8.02
Upside: +12.22%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.17
Upside: +93.42%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.16
Upside: +503.45%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $9.59
Upside: +317.10%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.86
Upside: +249.65%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $18.86
Upside: +6.07%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $2.93
Upside: +923.89%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $13.45
Upside: +167.66%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.29
Upside: +3,830.13%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.04
Upside: +1,630.77%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.91
Upside: +161.78%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $17.50
Upside: +471.43%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $10.66
Upside: +603.56%